Plasma concentration and pharmacological effects of pyridostigmine in patients with myasthenia gravis [proceedings]

Free article

T N Calvey et al. Br J Clin Pharmacol. 1977 Jun.

Free article

. 1977 Jun;4(3):404P.

doi: 10.1111/j.1365-2125.1977.tb00750.x.

No abstract available

Similar articles

Plasma concentration of pyridostigmine and effects in myastenia gravis.
Chan K, Calvey TN. Chan K, et al. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):596-601. doi: 10.1002/cpt1977225part1596. Clin Pharmacol Ther. 1977. PMID: 199393
Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
Breyer-Pfaff U, Schmezer A, Maier U, Brinkmann A, Schumm F. Breyer-Pfaff U, et al. J Neurol Neurosurg Psychiatry. 1990 Jun;53(6):502-6. doi: 10.1136/jnnp.53.6.502. J Neurol Neurosurg Psychiatry. 1990. PMID: 2166138 Free PMC article.
Quantitative correlation between plasma pyridostigmine levels and neuromuscular function in myasthenia gravis.
Milner-Brown HS, Mellenthin M, Sharma ML, Miller RG. Milner-Brown HS, et al. Neurology. 1987 May;37(5):800-3. doi: 10.1212/wnl.37.5.800. Neurology. 1987. PMID: 3574680
Neuromuscular blockade.
Neigh JL. Neigh JL. Surg Clin North Am. 1975 Aug;55(4):837-50. doi: 10.1016/s0039-6109(16)40685-7. Surg Clin North Am. 1975. PMID: 241125 Review. No abstract available.
Adverse drug effects on neuromuscular transmission.
Howard JF Jr. Howard JF Jr. Semin Neurol. 1990 Mar;10(1):89-102. doi: 10.1055/s-2008-1041258. Semin Neurol. 1990. PMID: 2161128 Review. No abstract available.